Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway

25 Nov 2024

Abstract excerpt

Metabolism-related pathways are important targets for intervention in the treatment of hepatocellular carcinoma (HCC), but few studies have reported on the combination of inhibitors of folate metabolism-related enzymes and molecularly targeted drugs for HCC. The results of the present work are the first to reveal the effects of an inhibitor of dihydrofolate reductase (DHFR), pralatrexate, on the sensitivity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Cytokine Signaling Pathways and Interactions
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39585461
DOI: 10.1007/s12672-024-01572-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathwayPMID 39585461Read ↗

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphomaSemantic proximity Read ↗

Characterization of Newly Established Pralatrexate-resistant Cell Lines and the Mechanisms of ResistanceSemantic proximity Read ↗

More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?Semantic proximity Read ↗

Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of actionSemantic proximity Read ↗

Folic acid depletion along with inhibition of the PERK arm of endoplasmic reticulum stress pathway promotes a less aggressive phenotype of hepatocellular carcinoma cells.Semantic proximity Read ↗

Targeting Mevalonate Pathway Enhances the efficacy of 5-Fluorouracil by regulating pyroptosisSemantic proximity Read ↗

A Three‐Pronged Epigenetic Approach to the Treatment of Hepatocellular CarcinomaSemantic proximity Read ↗

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Advances in NAD-Lowering Agents for Cancer TreatmentSemantic proximity Read ↗

HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancerSemantic proximity Read ↗

Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation.Semantic proximity Read ↗

Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.